Sagimet is a clinical-stage biopharmaceutical company developing novel FASN inhibitors designed to target dysfunctional metabolic and fibrotic pathways in conditions resulting from the overproduction ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results